Guselkumab for the treatment of psoriasis - evidence to date

Drugs in Context
Miguel Nogueira, Tiago Torres

Abstract

Psoriasis is a chronic, immune-mediated, inflammatory, and debilitating skin disease with significant impact on patients' quality of life. Its pathogenesis is complex and not yet fully understood. However, the IL-23/IL-17 axis is currently considered the main pathogenic pathway in psoriasis. Guselkumab is a fully human immunoglobulin G1 λ (IgG1λ) monoclonal antibody (mAb) that binds to the p19 subunit of IL-23. It is the first of its class, already approved by the US Food and Drug Administration (FDA), as well as the European Medicines Agency (EMA) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for either systemic therapy or phototherapy. Several clinical trials have demonstrated potential benefits of guselkumab over other already approved immunomodulators in terms of safety and efficacy. The results of the head-to-head trial ECLIPSE were recently released and are addressed in this review. They contribute to the increasing confidence in guselkumab, demonstrating great potential for long-term treatment of psoriasis. However, further long-term data and additional comparative studies will be essential for positioning guselkumab in the therapeutic armamentarium for psoriasis.

Citations

Apr 22, 2020·Immunotherapy·Cristina López-Sánchez, Lluís Puig
Jul 2, 2020·American Journal of Clinical Dermatology·Radomir ReszkeJacek C Szepietowski
Sep 29, 2020·Frontiers in Immunology·Mohamed A AlfalehAnwar M Hashem
Sep 5, 2020·Clinical, Cosmetic and Investigational Dermatology·Egídio FreitasTiago Torres
Dec 29, 2020·Frontiers in Neurology·Austin NegronThomas G Forsthuber
Oct 15, 2020·International Journal of Molecular Sciences·Michio Tokuyama, Tomotaka Mabuchi
Apr 4, 2021·Paediatric Drugs·Miguel NogueiraTiago Torres
May 1, 2021·International Journal of Clinical Practice·Teodora-Larisa TimisRemus-Ioan Orasan
Aug 11, 2021·Pharmaceutics·Jen-Chih TsengTsung-Hsien Chuang

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Clinical Trials Mentioned

NCT01483599
NCT02207231
NCT02207244
NCT02203032
NCT03090100
NCT03158285
NCT03162796
NCT03466411

Software Mentioned

VOYAGE
ECLIPSE
NAVIGATE

Related Concepts

Related Feeds